Challenges in the treatment of cystic fibrosis in the era of CFTR modulatorsAuthors' replyUse of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele a systematic review and meta-analysisDiscontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY) results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsAssessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.

Subjects

Subjects :

Humans
Pyridines therapeutic use
Pyrazoles therapeutic use
Pyrroles therapeutic use
Saline Solution, Hypertonic therapeutic use
Drug Combinations
Forced Expiratory Volume drug effects
Pyrrolidines
Cystic Fibrosis drug therapy
Cystic Fibrosis genetics
Benzodioxoles therapeutic use
Cystic Fibrosis Transmembrane Conductance Regulator genetics
Aminophenols therapeutic use
Indoles therapeutic use
Quinolones therapeutic use

Details

Language :

English

ISSN :

1806-3756

Volume :

50

Issue :

2

Database :

MEDLINE

Journal :

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia

Publication Type :

Editorial & Opinion

Accession number :

38808835

Full Text :

https://doi.org/10.36416/1806-3756/e20240107